Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 234

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

Open access
Kumar, Shaji, Giralt, Sergio, Stadtmauer, Edward A., Harousseau, Jean L., Palumbo, Antonio, Bensinger, William, Comenzo, Raymond L., Lentzsch, Suzanne, Munshi, Nikhil, Niesvizky, Ruben, San Miguel, Jesus, Ludwig, Heinz, Bergsagel, Leif, Blade, Joan, Lonial, Sagar, Anderson, Kenneth C., Tosi, Patrizia, Sonneveld, Pieter, Sezer, Orhan, Vesole, David, Cavo, Michele, Einsele, Hermann, Richardson, Paul G., Durie, Brian G. M., Rajkumar, S. Vincent · 2009 · Blood

Abstract

The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeutic option for patients with multiple myeloma eligible for the procedure. Before the advent of the novel agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given its potential deleterious effect on stem cell collection. With increasing use of the novel agents in the upfront setting, several reports have emerged raising concerns about their impact on the ability to collect stem cells. An expert panel of the International Myeloma Working Group (IMWG) was convened to examine the implications of these therapies on stem collection in patients with myeloma and to develop recommendations for addressing these issues. Here we summarize the currently available data and present our perspective on the problem and potential options to overcome this problem. Specifically, we recommend early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-04-205013

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 234

Metadata

Authors
Kumar, S., Giralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., Lentzsch, S., Munshi, N., Niesvizky, R., San Miguel, J., Ludwig, H., Bergsagel, L., Blade, J., Lonial, S., Anderson, K. C., Tosi, P., Sonneveld, P., Sezer, O., Vesole, D., Cavo, M., Einsele, H., Richardson, P. G., Durie, B. G. M., & Rajkumar, S. V.
Venue
Blood
Published
2009-08-27
Volume
114
Issue
9
Pages
1729-1735
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1986692982
Cited by
234
References
8
FWCI
16.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. https://app.cochat.ai/papers/10.1182/blood-2009-04-205013
The paper
Kumar, S., Giralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., Lentzsch, S., Munshi, N., Niesvizky, R., San Miguel, J., Ludwig, H., Bergsagel, L., Blade, J., Lonial, S., Anderson, K. C., Tosi, P., Sonneveld, P., Sezer, O., . . . Rajkumar, S. V. (2009). Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. https://doi.org/10.1182/blood-2009-04-205013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.